Green Cross Obtains South Korean Approval For BioCryst Influenza Therapy Peramivir
This article was originally published in The Pink Sheet Daily
The deal is part of a drive to secure anti-influenza options beyond Roche and GSK products in preparation for the next round of global influenza.
You may also be interested in...
TOKYO - Shionogi still has a few years to reap the benefits of Crestor royalties from AstraZeneca, but the looming generic substitution of rival Lipitor is forcing the company to prepare for a slowdown of its blockbuster drug. But according to Macquarie Equities Research, revised ex-U.S. Crestor prospects, strong pipeline prospects and recent launches could position Shionogi well in the near term
SEOUL - For the first time in its fight against A/H1N1, the Korea Food & Drug Administration allowed the use of injectable antiviral peramivir in a seriously-ill patient even though the product is not yet approved in South Korea
SEOUL - With or without an approval from Korea FDA, South Korea's vaccine producer Green Cross is gearing up to launch its version of injectable antiviral peramivir, which was developed by BioCryst Pharmaceuticals for treatment of influenza